Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Greenhaven Road Investment Management L.P.

Greenhaven Road Investment Management L.P. decreased its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 5.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,975,541 shares of the company's stock after selling 110,870 shares during the quarter. Cellebrite DI accounts for approximately 7.0% of Greenhaven Road Investment Management L.P.'s holdings, making the stock its 2nd largest position. Greenhaven Road Investment Management L.P. owned 0.96% of Cellebrite DI worth $43,521,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in CLBT. True Wind Capital Management L.P. boosted its holdings in shares of Cellebrite DI by 18.2% during the fourth quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock valued at $305,358,000 after acquiring an additional 2,130,386 shares during the period. FMR LLC grew its holdings in Cellebrite DI by 89.1% in the 4th quarter. FMR LLC now owns 10,621,344 shares of the company's stock worth $233,988,000 after buying an additional 5,004,587 shares in the last quarter. Pertento Partners LLP boosted its position in Cellebrite DI by 26.7% during the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company's stock worth $65,547,000 after acquiring an additional 626,373 shares during the period. Pembroke Management LTD grew its stake in shares of Cellebrite DI by 4.4% in the fourth quarter. Pembroke Management LTD now owns 1,992,432 shares of the company's stock worth $43,893,000 after purchasing an additional 84,087 shares in the last quarter. Finally, Crescent Park Management L.P. raised its stake in shares of Cellebrite DI by 8.3% during the fourth quarter. Crescent Park Management L.P. now owns 1,862,482 shares of the company's stock valued at $41,030,000 after purchasing an additional 142,534 shares in the last quarter. 45.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Lake Street Capital raised their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. raised their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $23.43.

Cellebrite DI Price Performance

NASDAQ CLBT traded up $0.88 on Wednesday, hitting $19.27. 416,289 shares of the company were exchanged, compared to its average volume of 1,405,711. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30. The firm has a market capitalization of $4.61 billion, a P/E ratio of -13.86, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The company's 50 day moving average price is $18.79 and its 200-day moving average price is $20.10.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, equities analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.